Sponsored by:

Video from SNMMI: Cathy Cutler on the state of the field in 2025

Will Morton, Associate Editor, AuntMinnie.com. Headshot
Will Morton
Jun 24, 2025

NEW ORLEANS -- In an interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, SNMMI President Cathy Cutler, PhD, discussed developments over the last year, as well as challenges facing the field moving ahead, such as securing stable supplies of radioisotopes. Cutler is chair of the Isotope Research and Production Department at Brookhaven National Laboratory in Upton, NY.

Latest in Molecular Imaging
Atom Nuclear Lab 400
Nusano, Ariceum Therapeutics sign multi-isotope supply agreement
October 14, 2025
Expand your field of view with new Biograph Trinion.X PET/CT
Sponsored
Expand your field of view with new Biograph Trinion.X PET/CT
October 6, 2025
Pet Ct Scanner
PET/CT shows value in patients with soft-tissue sarcomas
October 13, 2025
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
SNMMI updates radioisotope production status in U.S.
October 10, 2025
Related Stories
Wang Ioy Image Thumbnail
Molecular Imaging
SNMMI: New immuno-PET tracer awarded Image of the Year
Coronal fused FDG-PET/MRI image of a patient with right upper back pain demonstrates asymetric uptake in the right trapezius muscle without abnormality on MRI to suggest edema or denervation injury. Trigger point lidocaine injection of the area based on PET/MRI findings resulted in complete relief of symptoms (pain score reduced to 0 from a baseline of 6).
Molecular Imaging
SNMMI: PET/MRI helps manage patients with chronic spinal pain
Cathy Cutler Ph D Snmmi President 2024 Thumbnail
2024
Cutler named president of SNMMI
Expand your field of view with new Biograph Trinion.X PET/CT
Sponsor Content
Expand your field of view with new Biograph Trinion.X PET/CT
More in Molecular Imaging
Nusano, Ariceum Therapeutics sign multi-isotope supply agreement
By AuntMinnie.com staff writers
The agreement will give Ariceum access to Nusano-produced radioisotopes for its novel radiotherapeutics.
October 14, 2025
Atom Nuclear Lab 400
PSMA-PET/CT reporting varies widely in the U.S.
By Will Morton
Standardized interpretation frameworks for PSMA-PET/CT reporting are underused in the U.S.
October 14, 2025
2025 10 14 Incidental Findings Psma Pet Ct Thumbnail
PET/CT shows value in patients with soft-tissue sarcomas
By Will Morton
PET/CT scans can help identify which patients are most likely to benefit from treatment.
October 13, 2025
Pet Ct Scanner
SNMMI updates radioisotope production status in U.S.
By AuntMinnie.com staff writers
Projects noted in an October 10 update include IAEA's disused radium transfer program and others.
October 10, 2025
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
PSMA-PET/CT may replace NaF-PET/CT in advanced prostate cancer
By Will Morton
Replacing F-18 sodium fluoride (NaF) PET/CT with F-18 PSMA PET/CT can improve treatment for men with newly diagnosed prostate cancer.
October 10, 2025
2025 10 09 Jnumed Psma Pet Vs Na F Pet Thumbnail
GLP-1 drugs may confound PET/CT imaging findings
By AuntMinnie.com staff writers
The drugs are now widely prescribed for people with type 2 diabetes -- with a 700% use increase in the U.S. between 2019 and 2023.
October 7, 2025
Semaglutide Injection Pen
PSMA PET-guided radiotherapy shows promise
By Will Morton
A trial demonstrated that radiotherapy informed by PSMA-PET led to improved outcomes in prostate cancer patients.
October 3, 2025
Prostate Imaging
PET reveals mechanism underlying brain fog in long COVID
By Will Morton
Brain regions where C-11 K-2 radiotracer was increased were negatively correlated with long-COVID patients’ performance on cognitive tests.
October 2, 2025
2025 10 02 Long Covid Apar Thumbnail
SpectronRx’s Ac-225 boosted for use in Canada
By AuntMinnie.com staff writers
Ac-225 is a highly sought-after alpha-emitting isotope that shows promise for targeted cancer therapy.
October 1, 2025
Isotopes1
NAPT survey results show promise for proton therapy adoption
By Amerigo Allegretto
Proton therapy continues to experience increased clinical use, but barriers to care continue to limit its potential.
September 29, 2025
Survey Form 400
CPDC launches Cadena Research for radiopharmaceutical development
By AuntMinnie.com staff writers
The CPDC has launched Cadena Research, a new preclinical CRO offering support for early-stage radiopharmaceuticals.
September 29, 2025
Radiotherapy2 400
Case report: Pluvicto as a first-line treatment in late-stage prostate cancer
Since 1996, the patient continually declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland.
September 26, 2025
Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.
Page 1 of 615
Next Page